KalVista Pharmaceuticals, Inc. (KALV)
收市後：
| 前收市價 | 10.49 |
| 開市 | 10.50 |
| 買盤 | 10.76 x 100 |
| 賣出價 | 10.81 x 200 |
| 今日波幅 | 10.27 - 10.81 |
| 52 週波幅 | 7.21 - 16.88 |
| 成交量 | |
| 平均成交量 | 814,547 |
| 市值 | 454.79M |
| Beta 值 (5 年，每月) | 0.91 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -3.12 |
| 業績公佈日 | 2024年7月05日 - 2024年7月09日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 30.60 |
Barrons.comARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors
RA Capital increased its stake in biopharmaceutical firm ARS. Bain Capital lowered its stake in pharmaceutical firm Nuvalent.
- Reuters
UPDATE 1-KalVista meets main goals in late-stage trial for genetic disease
KalVista Pharmaceuticals said on Tuesday its therapy for a type of genetic condition, which causes rapid swelling under the skin and in other parts of the body, met main goals in a late-stage trial. The therapy, sebetralstat, showed beginning of symptom relief in patients with hereditary angioedema (HAE) significantly faster than placebo. The median time to beginning of symptom relief was 1.61 hours with the lower dose version of sebetralstat and 6.72 hours with placebo.
Insider Monkey16 Most Promising Long-Term Stocks According to Analysts
In this piece, we will take a look at the 16 most promising long-term stocks according to analysts. If you want to skip our overview of long term investing, then you can take a look at 5 Most Promising Long-Term Stocks According to Analysts. While investing comes in all sizes and flavors, the one approach […]
